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Abstract 
Introduction: Although prolonged small intestine and colonic transit time has been demonstrated in acromegaly patients, the influence of 
acromegaly on oesophagus motility and the pathological mechanisms involved are still not clarified. We aimed to investigate manometric 
measurements to ascertain whether oesophagus motility is affected in active acromegaly patients.
Material and methods: The study was performed in an institutional referral centre at a tertiary care hospital. Twenty-three acromegaly 
patients (mean age 43.2 ± 13.2 years) and 25 sex- and age-matched healthy control subjects (mean age 48.6 ± 7.9 years) were recruited to 
a case-control study. Oesophageal manometry was performed using MMS (Medical Measurement Systems, Netherlands) Solar GI — Air 
Charged Intelligent Gastrointestinal Conventional Manometry.
Results: In manometric measurements the lower oesophageal sphincter pressure was 18 ± 7 mmHg in acromegaly patients and 
15.6 ± 4.4 mm Hg in controls, and there was no significant difference (p = 0.17). The percentage of relaxation was 64.8% and 81.8%, 
respectively, and it was significantly lower in acromegaly patients than in controls (p < 0.001). Additionally, the duration of relaxation 
was found to be 4 ± 1.9 seconds and 5 ± 1.7 seconds in patients and controls, respectively (p = 0.049). 
Conclusions: Our study has demonstrated a significant reduction in the percentage and duration of lower oesophageal sphincter relaxation 
in oesophagus motility even in acromegaly patients without any gastrointestinal symptoms. Further clinical and pathophysiological studies 
are required to clarify the underlying mechanisms of gastrointestinal motility disorders in acromegaly. (Endokrynol Pol 2015; 66 (4): 308–312)
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Streszczenie
Wstęp: Chociaż u pacjentów chorujących na akromegalię wykazano wydłużony czas pasażu żołądkowo-jelitowego, wpływ akromegalii 
na motorykę przełyku oraz powiązane z tym mechanizmy patologiczne nadal nie są wyjaśnione. Celem pracy było zbadanie za pomocą 
pomiarów manometrycznych czy motoryka przełyku ulega zmianie u pacjentów z aktywną akromegalią.
Materiał i metody: Badanie przeprowadzono w ośrodku referencyjnym w szpitalu specjalistycznym. Dwudziestu trzech pacjentów 
chorujących na akromegalię (śr. wiek 43,2 ± 13,2 lat) oraz w grupie kontrolnej 25 osób dopasowanych pod względem płci i wieku 
(śr. wiek 48,6 ± 7,9 lat) zostało zakwalifikowanych do badania kliniczno-kontrolnego. Manometrię przełyku wykonano za pomocą MMS 
(Medical Measurement Systems, Holandia) Solar GI.
Wyniki: W pomiarach manometrycznych u pacjentów ciepiących na akromegalię, ciśnienie dolnego zwieracza przełyku wynosiło 
18 ± 7 mm Hg, a u osób kontrolnych wynosiło ono 15,6 ± 4,4 mm Hg, nie było więc znaczącej różnicy między grupami (p = 0,17). odsetek 
rozkurczu wynosił odpowiednio 64,8% i 81,8% i był on znacznie niższy u pacjentów z akromegalią (p < 0,001). Ponadto, długość trwania 
rozkurczu wynosiła odpowiednio 4 ± 1,9 sek. i 5 ± 1,7 sek. (p = 0,049).
Wnioski: Niniejsze badanie wykazało znaczną redukcję odsetka i czasu trwania rozkurczu dolnego zwieracza przełyku w motoryce 
przełyku, nawet u pacjentów z akromegalią bez objawów żołądkowo-jelitowych. Należy przeprowadzić dalsze badania kliniczne 
i patofizjologiczne, aby wyjaśnić mechanizmy leżące u podłoża zaburzeń motoryki żołądkowo-jelitowej u pacjentów chorujących na 
akromegalię. (Endokrynol Pol 2015; 66 (4): 308–312)
Słowa kluczowe: akromegalia; przełyk; ruchliwość; manometria
Introduction
Acromegaly is a rare disease that is mainly caused by 
pituitary somatotroph adenomas [1]. Hypersecretion of 
GH and IGF1 effect the whole body and lead to multi-
systemic complications, including those involving the 
gastrointestinal system [2, 3]. In terms of organic gas-
trointestinal disorders, adenomatous polyps and colon 
carcinoma are the most significant complications asso-
ciated with acromegaly [4]. Acromegaly has also been 
related with functional disorders of the gastrointestinal 
system in several reports. Along with prolonged small 
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intestine and colonic transit time, bacterial overgrowth 
has been demonstrated in acromegaly patients [5, 6]. 
Additionally, previous studies have shown that soma-
tostatin analogues in the treatment of acromegaly could 
impair gall bladder emptying, which leads to gallstones 
[7]. Autonomic intestinal impairment and possible roles 
of gastrointestinal hormones (e.g. ghrelin) have been 
postulated to explain the motility dysfunctions [8, 9]. 
However, the influence of acromegaly on gastrointes-
tinal system motility and the pathological mechanisms 
involved are still not clarified.
Oesophageal manometry is performed to measure 
motility function, and it provides the evaluation of 
the peristaltism and intraluminal pressure of the oe-
sophagus [10]. It is the most relevant technique in the 
diagnosis of oesophageal functional disorders such as 
achalasia and diffuse oesophageal spasm. Manometric 
assessments have also contributed to reveal the patho-
physiological mechanisms as well as clinical ground in 
gastrointestinal manifestations of endocrine diseases 
such as diabetes and thyroid disorders [11, 12]. Oe-
sophageal manometry is the gold standard technique 
for the evaluation of oesophageal functional disorders, 
and to our knowledge no data are available on oesopha-
gus motility in acromegaly patients. 
In this study we aimed to investigate the manomet-
ric measurements to assertain whether oesophagus 
motility is affected in active acromegaly patients.
Material and methods
Subjects
Twenty-three naive acromegaly patients (15 female and 
8 male) and 25 age- and sex-matched healthy subjects 
(17 female and 8 male) were recruited to the study in 
Bezmialem University Hospital Endocrinology Clinic 
between 2011 and 2013. Mean age was 43.2 ± 13.2 years 
in acromegaly patients and 48.6 ± 7.9 years in healthy 
subjects. All acromegaly patients were newly diagnosed 
and had no gastrointestinal system symptoms such as 
dyspepsia, dysphagia, reflux or regurgitation, early 
satiety, loss of appetite, nausea, abdominal fullness, di-
arrhoea, or constipation. Based on the clinical features, 
acromegaly was confirmed by unsuppressed GH to 
< 0.4 ng/mL after an oral glucose tolerance test and high 
IGF1 levels, age matched. Magnetic resonance imaging 
(MRI) of hypophysis was performed for all acromegalic 
patients and the maximum diameter was determined as 
the tumour size. The IGF1 values of every patient were 
adjusted to calculate the IGF1 index using the follow-
ing formula: 100*IGF1/Upper limit of normal range, 
because the upper limit of the normal range for IGF1 
values is variable according to age [13]. Blood GH and 
IGF1 levels were assayed using a chemiluminescence 
immunometric assay (Siemens Advia-Centaur USA). 
Age-related reference ranges for IGF1 were as follows: 
18–20 years old: 197–956; 20–23 years old: 215–628; 23–25 
years old: 169–591; 25–30 years old: 119–476; 30–40 years 
old: 100–494; 40–50 years old: 101–303; and > 50 years 
old: 78–258 (ng/mL).
Patients with a history of gastrointestinal tract 
disease, other diseases known to effect gastrointesti-
nal motility (diabetes mellitus, hypothyroidism, etc.), 
chronic systemic disorders (malignancies, infections), 
and those taking any medication that could influence 
gastrointestinal system motility, as well as those smok-
ing or drinking alcohol, were excluded from the study. 
Complete blood counts, sedimentation rate, routine 
biochemical blood tests (serum glucose, creatinine, 
electrolytes, albumin, total protein, liver enzymes) and 
vitamin B12 level measurements were also performed 
in all patients. 
This study was approved by the local ethics com-
mittee of Bezmialem Vakif University, and informed 
consent was obtained in all cases.
Oesophageal manometry
The parameters of oesophageal manometry were 
measured by using MMS (Medical Measurement 
Systems, Netherlands) Solar GI — Air Charged In-
telligent Gastrointestinal Conventional Manometry. 
A four-channel air charged circumferential pressure 
catheter (Latitude Gastrointestinal Manometry Cath-
eter Clinical innovations, Inc. 747 West 4170, South 
Murray, Utah) with a 5-cm distance between sensors 
was inserted via a nostril and then placed to straddle 
the gastroesophageal junction. After an overnight 
fast, oesophageal motility in patients with acromegaly 
and healthy subjects were performed in the supine 
position. The lower oesophageal sphincter pressure 
(LESP) was measured as the difference between the 
end-expiratory LESP and the end-expiratory gastric 
pressure, applying the station pull-through technique. 
All pressure values were given in mm Hg and referred 
to atmospheric pressure. The four sensors positioned 3, 
8, 13, and 18 cm above the lower oesophageal sphinc-
ter (LES) were used to calculate contractions in the 
oesophageal body. Ten consecutive wet swallows at 
30-second intervals (5 mL of water) were measured. 
Dry swallows were excluded in the analysis. Only one 
investigator performed all tracings. 
The wave amplitude from the mean intraesophageal 
baseline pressure to the peak of the wave was included 
in the measurements. The duration of individual con-
tractions was calculated from the initiation of the major 
upstroke to the termination of the wave. The percentage 
of peristalsis was recognised among the 10 consecutive 
wave forms.
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Statistical analysis
Statistical analyses were performed with SPSS software, 
version 20.0 for windows (SPSS Inc., Chicago, IL, USA). 
Since the distribution of values was normal, Student’s 
t test was used for comparison of the means of two 
groups. Pearson’s correlation was applied to evaluate 
the relationship between the studied parameters. Sta-
tistical significance was set at p < 0.05. The quantitative 
variables are presented as mean ± standard deviation. 
Results
Table I summarises the demographic characteristics 
of acromegaly patients and healthy controls. Age and 
gender were similar in both groups. Body mass index 
was 29.1 ± 4.4 in acromegaly patients and 27.7 ± 3.3 
in healthy subjects, and there was no significant differ-
ence (p > 0.05). Mean GH level was 8.7 ± 10.8 ng/mL and 
mean IGF1 level was 788.4 ± 332.3 ng/mL in acromegaly 
patients. Adjusted IGF1 levels according to the upper 
limit of normal range was 3.2 ± 1.4 ng/mL. Sixteen 
(69.6%) patients had macroadenomas and 7 (30.4%) had 
microadenomas in the acromegaly group. Laboratory 
findings and clinical assessment showed no hypopitui-
tarism or any other endocrinological disorders except 
for acromegaly in the patient group. 
All parameters in oesophageal manometric measure-
ments were compared between acromegaly patients and 
control group. The mean lower oesophageal sphincter 
pressure (LESP) was 18 ± 7 mm Hg in acromegaly 
patients and 15.6 ± 4.4 mm Hg in controls, and there 
was no significant difference between these two groups 
(p = 0.17) (Fig. 1). The duration of contraction was 3.7 
± 0.8 seconds in acromegaly patients and 3.7 ± 0.6 sec-
onds in healthy subjects (p > 0.05). Maximum upstroke 
also displayed no significant difference between groups 
(71.5 ± 21.1 mm Hg in acromegaly patients and 68.1 ± 
24.6 mm Hg in healthy subjects). The percentage of re-
laxation for acromegaly patients and control group was 
64.8% and 81.8%, respectively, which was significantly 
lower for acromegaly patients than for healthy subjects 
(p < 0.001) (Fig. 2). Furthermore, the duration of relaxation 
was found to be 4 ± 1.9 seconds in acromegaly patients 
and 5 ± 1.7 seconds in the control group, and it was 
significantly shorter in patients with acromegaly than in 
controls (p = 0.04). No correlation was observed between 
manometric measurements and disease characteristics, 
including GH, IGF1, adjusted IGF1, and tumour size.
Table I. Demographic Characteristics of Acromegaly Patients 
and the Control Group
Tabela I. Cechy demograficzne grupy pacjentów z akromegalią 
i grupy kontrolnej
  Acromegaly 
Patients 
(n = 23)
Control Group 
(n = 25)
p
Age (y) 43.2 ± 13.2 48.6 ± 7.9 N.S.
Gender Female (n) 15 17 N.S.
Male (n) 8 8
BMI [kg/m2] 29.1 ± 4.4 27.7 ± 3.3 N.S.
GH [ng/mL] 8.7 ± 10.8
IGF1 [ng/mL] 788.4 ± 332.3
IGF1 index 3.2 ± 1.4
Tumour Size (n, %)
Macroadenoma 16 (69.6)
Microadenoma 7 (30.4)
Data are mean ± Standard Deviation 
IGF1 index: 100*IGF1/Upper limit of normal range
Figure 1. Distribution of (A) LESP and (B) maximum upstroke in acromegaly patients and control group (p > 0.05 for both manometric 
parameters)
Rycina 1. Rozkład (A) ciśnienia dolnego zwieracza przełyku oraz (B) maksymalnej relaksacji u pacjentów z akromegalią i grupy 
kontrolnej (p > 0,05 dla obu parametrów manometrycznych)
A B
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Discussion
Colorectal neoplasms are the most prevalent and 
clinically well-known gastrointestinal complications 
of acromegaly [14, 15]. In clinical studies and reviews, 
functional disorders of the gastrointestinal system 
in acromegaly have been overshadowed by organic 
disorders. Moreover, there are a very limited number 
of studies focused on gastrointestinal functional disor-
ders in acromegaly, and it has been shown that active 
acromegaly may induce impairment of the intestinal 
motility [16]. Resmini et al. revealed prolonged oro-cecal 
transit time and small intestinal bacterial overgrowth in 
acromegaly patients [5], and Catnach et al. found that 
gall bladder motor function was severely impaired in 
untreated acromegaly patients [17]. In another study 
reporting on gall bladder emptying and small intestinal 
transit in acromegaly patients, Hussaini et al. showed 
that intestinal transit and gall bladder volume were 
significantly different between acromegaly patients and 
controls [18]. Our results contribute to previous studies 
by indicating motility abnormalities of the oesophagus 
and by suggesting that acromegaly could have unfa-
vourable effects on oesophageal motility through the 
mechanisms of reduced percentage and duration of LES 
relaxation in patients without any clinical gastrointes-
tinal symptoms. Moreover, LESP was also found to be 
slightly higher in acromegaly patients than in control 
subjects, albeit insignificantly.
Plausible mechanisms have been elucidated that 
might explain gastrointestinal motility alterations in 
acromegaly, and the underlying pathogenesis remains 
unclear. Motility disorders in acromegaly could be linked 
to the presence of autonomic dysfunction, similar to that 
which have been previously demonstrated in the cardio-
vascular system [8, 19, 20]. LES is comprised of smooth 
muscle, and vagal efferent nerve induces its relaxation 
mediated by NO, which is the main neurotransmitters 
in the gastrointestinal tract [21–23]. It was shown that 
acromegaly can precipitate low levels of NO [24, 25]. 
Ronconi et al. found significantly decreased levels of 
NO concentrations in 13 acromegalic patients, compared 
to 12 sex- and age-matched controls, and an inverse 
correlation of NO levels with GH and IGF1 [26]. LES is 
also stimulated by postganglionic sympathetic nerves, 
although vagal innervation is responsible for the main 
regulator action. Previous studies showed sympathetic 
hypertonia indicating sympathovagal imbalance in ac-
romegaly patients [19]. In our study, the decreased per-
centage and duration of LES relaxation in acromegaly 
patients could be related to sympathovagal imbalance 
due to sympathetic hypertonia and decreased NO levels, 
which contribute to the impairment of relaxation and 
increase of LES basal tone in acromegaly [23]. Other 
studies have also shown that alterations in gastroin-
testinal hormones, including ghrelin and somatostatin 
(SS), can cause motility dysfunctions. Ghrelin enhances 
upper gastrointestinal motility and gastric emptying 
through the vagus nerves [27–29]. It has been shown 
that there is a feedback mechanism between ghrelin, SS, 
and GH, which might be considered one of the possible 
reasons for oesophageal motility dysfunction in patients 
with acromegaly [9, 30–32]. Arosio et al. indicated that 
GH stimulates hypothalamic SS production, as found 
in acromegaly, and that it may influence circulating SS 
levels, which might play a role in gastrointestinal motil-
ity disorders such as prolonged bowel transit in acro-
megaly patients [33]. However, the pathophysiological 
mechanisms of gastrointestinal motility disorders still 
need clarification, and further studies are required.
Figure 2. Distribution of (A) duration of LES relaxation and (B) percentage of LES relaxation in acromegaly patients and control 
group (p < 0.05 and p < 0.001, respectively)
Rycina 2. Rozkład (A) Czasu trwania rozkurczu LES oraz (B) procentowej relaksacji LES u pacjentów z akromegalią i grupy kontrolnej 
(odpowiednio, p < 0,05 i p < 0,001)
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Correlations between well-known complications 
and levels of GH and IGF1 are still a matter of debate. 
Along with increased risk for mortality and morbidity 
in acromegaly patients, non-biochemical parameters 
do not necessarily correlate with biochemical activity of 
acromegaly [34, 35]. Correlations between levels of GH 
and IGF1 and motility parameters were not reported 
in previous acromegaly studies. In this study no cor-
relation was found between the level of biochemical 
activity of acromegaly and manometric parameters. 
These results suggested that acromegaly impairs the 
relaxation of LES independently of levels of GH and 
IGF 1 hypersecretion.
In conclusion, we investigated for the first time oe-
sophageal motility manifestations in naive acromegalic 
patients. This study has demonstrated a significant 
reduction of the percentage and duration of LES relaxa-
tion in oesophagus motility even in acromegaly patients 
without any gastrointestinal symptoms. Further clinical 
and pathophysiological studies are required to clarify 
the underlying mechanisms of gastrointestinal motility 
disorders in acromegaly.
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